A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID).
Pierre MalchairAurema OteroJordi GiolXavier SolanichThiago CarnavalAlonso Fernández-NistalAna Sánchez-GabrielCarmen MontotoRamon LleonartSebastián Videlanull nullPublished in: Trials (2022)
gov NCT04978051.
Keyphrases
- phase ii
- open label
- sars cov
- clinical trial
- double blind
- study protocol
- phase iii
- mechanical ventilation
- coronavirus disease
- placebo controlled
- phase ii study
- end stage renal disease
- randomized controlled trial
- respiratory syndrome coronavirus
- ejection fraction
- intensive care unit
- acute respiratory distress syndrome
- healthcare
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- radiation therapy
- emergency department
- patient reported outcomes
- acute care
- squamous cell carcinoma
- rectal cancer
- respiratory failure